Accéder au contenu
Merck

TRIM37 promotes tumor cell proliferation and drug resistance in pediatric osteosarcoma.

Oncology letters (2017-11-23)
Yanling Tao, Meiyun Xin, Huanchen Cheng, Zongxuan Huang, Tiantian Hu, Teng Zhang, Jianlong Wang
RÉSUMÉ

Osteosarcoma (OS) is among the most frequently occurring bone tumors, particularly in children. Clinical treatment of OS is limited due to several factors including resistance to chemotherapy drugs and metastasis, and the underlying molecular mechanisms remain unclear. In the present study, tripartite motif containing 37 (TRIM37) expression levels were upregulated in tumor samples and associated with the development of drug resistance in OS. Furthermore, chemotherapy drug treatment (doxorubicin, cisplatin and methotrexate) induced TRIM37 expression in OS cells

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
(R)-MG132
Sigma-Aldrich
Z-Leu-Leu-Leu-al, ≥90% (HPLC)